22:27 , Feb 2, 2018 |  BioCentury  |  Finance

Building momentum

Avrobio Inc. parlayed positive clinical data and an aggressive in-licensing strategy into a $60 million series B round that will fund early clinical development of three long-acting lysosomal storage disease candidates. Cormorant Asset Management and Surveyor...
13:13 , Feb 1, 2018 |  BC Extra  |  Financial News

Cell therapy play Avrobio raises $60M

Avrobio Inc. (Cambridge, Mass.) raised $60 million in a series B round co-led by Cormorant Asset Management and Surveyor Capital. Fellow new investors Aisling, Brace Pharma Capital, Eventide, Morningside and Leerink Partners also participated alongside...
19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other molecule...
21:41 , Dec 1, 2017 |  BC Week In Review  |  Company News

Avrobio acquires cystinosis program from GenStem

In October, GenStem Therapeutics Inc. (San Diego, Calif.) granted Avrobio Inc. (Cambridge, Mass.) exclusive, worldwide rights to cystinosis gene therapy AVR-RD-04. Financial details are not disclosed. GenStem, a University of California San Diego spinout, will conduct...